Someone needs to tell Michel Vounatsos that he suffers from a terrible case of tin ear syndrome.
At a time when many Americans are increasingly angry over the cost of medicines, the Biogen chief executive last June slapped a $56,000 price tag on its newly approved Alzheimer’s treatment.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
